Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments
There is no Profile data available for LLY.SG.
744.6 | |
751.6 | |
- | |
751.6 | |
743.5 | |
512.3904-881.8966 | |
206 794 M | |
0 | |
0 | |
0.0144 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments
Amgen stock was dropping in premarket trading, despite positive data from a Phase 2 study for its experimental weight-loss drug, MariTide. The pharmaceutical company said in a statement that after 52 ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: